Add 2 More Reports For 20% off

Report Overview

Acne vulgaris is a common occurrence in both young adults and adolescents. The prevalence rates range from 35-90% in adolescents. Moreover, 12% of the women and 3% of the men aged over 25 may also develop the condition. Hence, researchers and key healthcare companies are focused on creating a range of highly effective drugs that cater to a wider cohort of patients. This influences the drug pipeline significantly.

Key Takeaways

  • Major companies involved in the severe acne vulgaris pipeline drugs market include Allergan, Novartis Pharmaceuticals, Pfizer and Incyte Corporation
  • Leading drugs currently under pipeline include PF-05175157, RA-18C3 and FMX101 among others.
  • Regulatory authorities such as the United States FDA and EMA play an essential role in the drug pipeline for severe acne vulgaris as they are offering breakthrough designations to manage the condition.

 
Report Coverage

The Severe Acne VulgarisDrug Pipeline Insight Report by Expert Market Research gives comprehensive insights into severe acne vulgaris drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for severe acne vulgaris. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The severe acne vulgaris pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from severe acne vulgaris.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to severe acne vulgaris.

Severe Acne Vulgaris Drug Pipeline Outlook

Acne vulgaris is a chronic form of acne, characterized by the formation of inflammatory or non-inflammatory skin lesions. It commonly affects the face, but it may spread to the neck, back or chest in some cases. It is commonly triggered by a bacterial species called Cutibacterium acnes and mostly affects young adults. Common symptoms include excessive sebum production, follicular plugging with keratinocytes and colonization by the bacteria. Hormonal imbalance, high sweating, occlusive cosmetics or skin care can be other causes of acne vulgaris.

Treatment for severe acne vulgaris depends on skin type, area and type of lesions as well as grade of acne. Acne is graded in the severe category when the total lesion count is more than 125, the total inflammatory count is greater than 50 and the total comedo is higher than 100. In October 2023, Bausch Health’s Cabtreo (triple combination gel) for treating acne in individuals aged 12 or above. Such drug approvals are expected to stimulate more research, thereby, impacting the drug pipeline for severe acne vulgaris positively.

Severe Acne Vulgaris – Drug Pipeline Therapeutic Assessment 

This section of the report covers the analysis of severe acne vulgaris drugs based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:

  • Antibiotics
  • Retinoids
  • Hormonal Agents
  • Anti-inflammatory Drugs

By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.

  • Oral
  • Parenteral
  • Topical
  • Others

Severe acne vulgaris – Pipeline Assessment Segmentation, By Phases 

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for severe acne vulgaris. There are around 47 drugs in phase II of severe acne vulgaris drugs.

Severe Acne Vulgaris – Pipeline Assessment Segmentation, By Drug Classes 

The drug molecules categories covered under severe acne vulgarispipeline analysis include antibiotics, retinoids, hormonal agents, and anti-inflammatory drugs. Antibiotics like doxycycline, minocycline, and tetracycline may be advised for treating bacterial infections while anti-inflammatory drugs such as corticosteroids can be taken orally or injected into the acne lesion. Drugs are based on the patient’s profile and the severity of the condition.

Severe Acne VulgarisClinical Trials Therapeutic Assessment – Competitive Dynamics 

The EMR report for the severe acne vulgarisdrug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in severe acne vulgaris clinical trials:

  • Allergan
  • Novartis Pharmaceuticals
  • Pfizer
  • Incyte Corporation
  • AbbVie
  • UCB Biopharma SRL
  • Janssen Research & Development, LLC
  • Almirall, S.A.
  • Vyne Therapeutics Inc.
  • LEO Pharma

Severe Acne Vulgaris– Emerging Drugs Profile 

PF-05175157

Pfizer's PF-05175157 is in Phase 2 of a 6-week randomized, double-blind, placebo-controlled study. It is under evaluation for its safety and tolerability against treating moderate to severe acne vulgaris in adults.

RA-18C3

RA-18C3 is a human monoclonal antibody, currently in Phase 2 of a 91-day open label trial for treating moderate to severe acne vulgaris in subjects. Sponsored by Janssen Research & Development, LLC, the participants will receive doses on days 0, 21, and 42 (with a total of 3 injections).

FMX101

FMX101 is a topical foam that contains 4% minocycline. Sponsored by Vyne Therapeutics, Inc., it is Phase 3 of a randomized, double-blind, vehicle-controlled study to investigate its safety and efficacy for treating moderate-to-severe acne vulgaris.

Topical SB204

Sponsored by Novan Inc., it is Phase 1 of a single-center, open-label study. The topical is under investigation to treat adolescents with moderate to severe acne vulgaris. The study involves taking blood samples from the participants on Day 1 and Day 21 to characterize systemic exposure to hMAP3 and nitrate.

Reasons To Buy This Report 

The Severe Acne Vulgaris Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for severe acne vulgaris. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within severe acne vulgaris pipeline insights.

Key Questions Answered in the Severe Acne Vulgaris– Pipeline Insight Report

  • What is the current landscape of severe acne vulgaris pipeline drugs?
  • How many companies are developing severe acne vulgaris drugs?
  • How many phase III and phase IV drugs are currently present in severe acne vulgaris pipeline drugs?
  • Which companies/institutions are leading the severe acne vulgaris drug development?
  • What is the efficacy and safety profile of severe acne vulgaris pipeline drugs?
  • What are the opportunities and challenges present in the severe acne vulgaris drug pipeline landscape?
  • Which company is conducting major trials for severe acne vulgaris drugs?
  • What geographies are covered for severe acne vulgaris clinical trials?
  • What are emerging trends in severe acne vulgaris clinical trials?

Related Reports

Global Severe Acne Vulgaris Treatment Market

Acne Therapeutics Market

Global Clinical Trials Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report Details
Drug Pipeline by Clinical Trial Phase
  • Late-Stage Products (Phase III and Phase IV)
  • Mid-Stage Products (Phase II)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
Route of Administration
  • Oral
  • Parenteral
  • Topical
  • Others
Drug Classes
  • Antibiotics
  • Retinoids
  • Hormonal Agents
  • Anti-inflammatory Drugs
Leading Sponsors Covered
  • Allergan
  • Novartis Pharmaceuticals
  • Pfizer
  • Incyte Corporation
  • AbbVie
  • UCB Biopharma SRL
  • Janssen Research & Development, LLC
  • Almirall, S.A.
  • Vyne Therapeutics Inc.
  • LEO Pharma
Geographies Covered
  • North America
  • Europe
  • Asia Pacific
  • Others

Purchase Full Report

Datasheet

 

USD 2,199

USD 1,899

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 2,749

USD 2,299

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 3,849

USD 3,299

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 4,949

USD 4,199

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124